Over a recent six-year period, all but one of the best-selling prescription drugs in the U.S. experienced “substantial” increases in cost, regardless of how long the medicines had been on the market or whether generic competition existed, according to a new study.

Of 49 medicines that were available between 2012 and 2017, the median increase in insurer and out-of-pocket patient costs was 76%. Drilling down further, the researchers looked at the 36 drugs that became available only as of 2012, and they found that costs rose for 28 of them by more than 50%. Prices more than doubled for another 16 medicines. And costs rose at least once, and sometimes twice, each year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy